Assessment of patients requiring an ‘’as needed treatment’’ with alemtuzumab therapy for resumed Multiple Sclerosis (MS) disease activity following the second dose of alemtuzumab from a single MS Centre in the North East of England
By Dr Alyaa H.A. Eissa, Neurology registrar ST5, Newcastle upon Tyne Hospitals NHS Foundation Trust
Project poster
Project write up
More MS Academy Medication Projects
Intravenous vs Subcutaneous Natalizumab With Extended Interval Dosing: A Comparison
By Dr Pavlos Theodorou, neurology specialty registrar, University Hospitals Coventry and Warwickshire NHS Trust
Introduction Of Extended-Interval Dosing Of Ocrelizumab To Patients With Hypogammaglobulinaemia
By Mairi Cromarty, neurosciences clinical pharmacist, NHS Lothian
Audit on use of Ponesimod in treatment of Relapsing Remitting Multiple Sclerosis in Teeside
By Dr Tanvi Shukla, stroke medicine locum consultan, North Tees and Hartlepool NHS Foundation Trust
Encouraging excellence, developing leaders, inspiring change
MS Academy was established five years ago and in that time has accomplished a huge amount. The six different levels of specialist MS training are dedicated to case-based learning and practical application of cutting edge research. Home to national programme Raising the Bar and the fantastic workstream content it is producing, this is an exciting Academy to belong to.